Does mirtazapine (Remeron) require tapering when reducing the dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirtazapine Requires Tapering When Discontinuing

Yes, mirtazapine should be tapered when reducing or discontinuing the dose to prevent withdrawal symptoms, and patients should not abruptly stop this medication. 1

Evidence for Tapering Requirement

FDA Drug Label Guidance

The FDA-approved labeling for mirtazapine explicitly states that patients should not abruptly discontinue mirtazapine and must discuss any tapering regimen with their healthcare provider, as adverse reactions can occur when the medication is discontinued 1. This is the strongest directive available and should guide clinical practice.

Clinical Evidence of Withdrawal Risk

A documented case report demonstrates the serious consequences of abrupt mirtazapine discontinuation: a patient who stopped 30 mg/day abruptly after 10 weeks of treatment developed severe, recurrent panic attacks starting on day 2 after cessation 2. These attacks occurred every 1-2 hours for 5 days and persisted at reduced frequency (once weekly) until mirtazapine was restarted, at which point symptoms completely resolved 2. This case clearly illustrates that even after medium-duration therapy (10 weeks), progressive tapering is advisable rather than abrupt cessation 2.

General Antidepressant Tapering Principles

Standard Tapering Duration

General guidelines for antidepressants recommend discontinuing over 10-14 days to limit withdrawal symptoms 3. However, this represents a minimum duration, and slower tapers may be necessary depending on individual patient factors and duration of treatment 4.

Why Tapering Matters

Antidepressant discontinuation syndrome is a recognized clinical entity that can be severe enough to compel patients to restart their medication 4. The syndrome can be mistaken for recurrence of the underlying depression, potentially leading to unnecessary long-term medication continuation 4.

Practical Tapering Approach for Mirtazapine

Recommended Strategy

  • Start with dose reductions rather than abrupt cessation 3, 1
  • The first dose reduction is critical—it must go well to establish patient confidence in the tapering process 5
  • Monitor closely for withdrawal symptoms including anxiety, panic attacks, sleep disturbances, and somatic complaints 2

Duration Considerations

While the general 10-14 day taper is a starting point 3, the documented case of withdrawal after only 10 weeks of treatment suggests that longer tapers may be prudent, particularly for patients who have been on mirtazapine for extended periods or at higher doses 2.

Monitoring During Taper

Watch specifically for:

  • Panic attacks or severe anxiety 2
  • Palpitations, dyspnea, chest pain 2
  • Dizziness, nausea, blurred vision 2
  • Sleep disturbances 2

Important Clinical Caveats

Never discontinue mirtazapine abruptly, even for surgical procedures or other medical interventions 2. The case report specifically involved abrupt cessation for an imminent surgical procedure, which precipitated severe withdrawal 2.

If withdrawal symptoms emerge during tapering, consider:

  • Slowing the taper rate
  • Temporarily returning to the previous dose
  • Restarting the medication if symptoms are severe and persistent 2

Key Distinction from Other Medications

Unlike benzodiazepines, which have specific structured tapering protocols (25% reductions every 1-2 weeks) due to seizure risk 6, mirtazapine does not have a single universally prescribed taper schedule. However, the principle remains the same: gradual dose reduction is mandatory to prevent withdrawal symptoms 1, 2.

The lack of anticholinergic and serotonergic side effects that characterize mirtazapine's tolerability profile 7, 8 does not eliminate the risk of withdrawal symptoms upon discontinuation—these are separate phenomena 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antidepressant Tapering Is Not Routine But Could Be.

Journal of the American Board of Family Medicine : JABFM, 2023

Guideline

Benzodiazepine Tapering Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.